ClinicalTrials.gg
CompletedNCT05119348TRACEUpdated Aug 9, 2024Results posted

Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments

An interventional study of STOPCOV in Covid19 and Sars-CoV-2 Infection, sponsored by Desmond Tutu HIV Foundation. Completed at 1 site in South Africa. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Desmond Tutu HIV Foundation · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Sep 2020, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
245
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in COVID-19 with a site in South Africa — 7 open to participants now, 9 under way, 5 of them phase 3. COVID-19 · South Africa.

Enrollment
58th of 95
245 · median 384
Started
2020
with 37 others
No phase
4 of 109
none open now
Registered
72nd of 109
by date

Among the 109 studies in COVID-19 with a site in South Africa, this one is the 58th largest by enrollment of the 95 interventional ones that give a count, is one of 38 that started in 2020, is one of 4 with no phase, and was the 72nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

7 of the 109 studies in COVID-19 with a site in South Africa are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in COVID-19 with a site in South Africa, or all of them as a file.
02

Study summary

South Africa recorded it's first coronavirus disease 2019 (COVID19) case on March 5, 2020. In response to the COVID19 outbreak World Health Organisation recommendations, South Africa implemented non-pharmaceutical recommendations. The major risk mitigation factors recommended by World Health Organisation and others - physical distancing and hygiene - are extremely difficult to implement in much of Africa. The investigators will conduct a randomised controlled trial to investigate the effect of an infection mitigation intervention to assess the effect on household transmission of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 in household settings with an index patient diagnosed SARS-CoV-2 positive.

Read the detailed description

The major risk mitigation factors recommended by World Health Organisation and others - physical distancing and hygiene - are extremely difficult to implement in much of Africa. Newly diagnosed SARS-CoV-2 index patients will be identified and recruited from a mobile clinic and local community clinics conducting SARS-CoV-2 testing. Index cases and their households will be invited to enroll. The study design is a type 2 hybrid cluster (household) randomised controlled trial, with outcomes assessed on index patients and their household contacts. 120 consecutively newly diagnosed index patients (GeneXpert severe acute respiratory syndrome coronavirus 2 PCR) and up to 6- 8 household contacts will be invited to participate in the trial as part of the prospective observational study evaluating transmission and symptoms. After completing consent, households will be randomised in a 1:1 ratio in blocks of 10 (60 households per group). Klipfontein is a resource-limited, densely populated, high HIV/tuberculosis disease burden areas in Cape Town. Newly diagnosed COVID19 cases will be identified from two sources: screening conducted in Desmond Tutu Health Foundation mobile screening units and local public sector clinics working closely with Desmond Tutu Health Foundation. Consecutive cases (n=120 cases and households) will be invited to participate in the randomised trial and prospective longitudinal follow up of up to 6- 8 household contacts. The contacts will be followed up after informed consent to SARS-CoV-2 screening, symptomatic questionnaires weekly up to 1 month. After enrolment, the household will be randomised to the infection mitigation intervention or enhanced usual care messaging. Baseline demographic, household characteristics questionnaire will be administered, and each household occupant invited to participate. Following consent procedures, household contacts (HHC) will be screened at baseline and weekly for 4 weeks for evidence of COVID19 infection. Specifically, the research team will conduct SARS-CoV-2 GeneXpert PCR testing and antibody serology. They will collate self- administered daily symptom checks on a weekly basis. The investigators will recruit 120 households over 1-11 months. The investigators will initiate a prospective longitudinal follow up of the household contacts of each case for 4 weeks in each case.

The investigators will calculate proportion of SARS-CoV-2 transmission from index cases in each household over 4- week period and describe the proportion of symptomatic and asymptomatic SARS-CoV-2 infection in a high density, low resourced community. Investigate the impact of the infection mitigation intervention by comparing incidence in households randomised to intervention versus standard of care. Secondary outcomes for the trial will include clinical outcomes (hospitalisations, death), linkages to care for people, psychosocial functioning, and stigma.

03

Conditions studied

  • Covid19
  • Sars-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • recently diagnosed SARS-CoV-2 positive
  • Individual >12 years
  • Able to give assent if \<18 years with parental/guardian consent
  • Able to give consent> 18 years
  • Self-isolating at home at the time of COVID diagnosis

Exclusion criteria

Exclusion Criteria:

  • \<12 years
  • Unable to give consent
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
245 participants (actual)

Study arms

  • Experimental
    Stop coronavirus (STOPCOV)

    A fieldworker will deliver the STOPCOV pack and personal protective equipment at baseline. The fieldworker will communicate with intervention households daily, delivering STOPCOV hygiene information.

    Other: STOPCOV

  • No intervention
    Control

    Participants received no additional messaging about managing COVID19 in the household.

Interventions

  • OtherSTOPCOV

    Fieldworkers delivered an infection mitigation intervention which consisted of personal protective equipment and messaging on managing COVID19 and reducing onward transmission of SARS-CoV-2 infection.

06

What researchers measure

Primary outcomes

  1. SARS-CoV-2 Infection

    Number of participants with positive SARS-CoV-2 PCR result

    Time frame: 4 weeks

Secondary outcomes

  1. COVID19 Symptoms

    Number of participants with SARS-CoV-2 serology antibody positive result

    Time frame: 4 weeks

07

Results

Posted Aug 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneStop Coronavirus (STOPCOV)Control
Started137108
Completed137108
Not completed00

Outcome measures

PrimarySARS-CoV-2 Infection

Number of participants with positive SARS-CoV-2 PCR result

Time frame:
4 weeks
Reported as:
Count of participants · Participants
SARS-CoV-2 Infection
ParticipantsStop Coronavirus (STOPCOV)Control
SARS-CoV-2 Infection42
SecondaryCOVID19 Symptoms

Number of participants with SARS-CoV-2 serology antibody positive result

Time frame:
4 weeks
Reported as:
Count of participants · Participants
COVID19 Symptoms
ParticipantsStop Coronavirus (STOPCOV)Control
COVID19 Symptoms119

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stop Coronavirus (STOPCOV)0/137 (0%)0/137 (0%)15/137 (10.9%)
Control0/108 (0%)0/108 (0%)4/108 (3.7%)
Most frequent other events
Most frequent other events
EventStop Coronavirus (STOPCOV)Control
Pressure in chestRespiratory, thoracic and mediastinal disorders7/1372/108
Shortness of breathRespiratory, thoracic and mediastinal disorders6/1371/108
Somnolence/ drowsy/ sleepyRespiratory, thoracic and mediastinal disorders2/1370/108
Confused/ disorientedRespiratory, thoracic and mediastinal disorders0/1371/108

Baseline characteristics

Age, Continuous
Age, Continuous(years)Stop Coronavirus (STOPCOV)ControlTotal
Mean38.4 ± 16.639.9 ± 17.139.1 ± 16.8
Sex: Female, Male
Sex: Female, Male(Participants)Stop Coronavirus (STOPCOV)ControlTotal
Female7960139
Male5848106
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stop Coronavirus (STOPCOV)ControlTotal
Race — Black692291
Race — Coloured6882150
Race — Indian033
Race — Prefer not to say011
Region of Enrollment
Region of Enrollment(participants)Stop Coronavirus (STOPCOV)ControlTotal
South Africa137108245
08

Study locations

1 site
  • Desmond Tutu Health Foundation
    Cape Town, WC 7925, South Africa
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There are no plans to share individual participant data with other researchers.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Aug 2021, 10 months.

Results were first posted in Aug 2024, 3 years after primary completion.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 10 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2021
First posted
Nov 15, 2021
StartActual
Sep 14, 2020
Primary completionActual
Aug 4, 2021
CompletionActual
Oct 21, 2021
Results first posted
Aug 9, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05119348
Lead sponsor
Desmond Tutu HIV Foundation
Collaborators
Amsterdam Institute for Global Health and Development, European and Developing Countries Clinical Trials Partnership (EDCTP), University of Cape Town
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Sep 14, 2020
Primary completion
Aug 4, 2021
Completion
Oct 21, 2021
Results posted
Aug 9, 2024
Last update
Aug 9, 2024

Study contacts

Linda-Gail Bekker, MBChB, PhD
principal investigator · Desmond Tutu Health Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion